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Background & objectives: In spite of the fact that BCG is the most widely used vaccine, tuberculosis (TB) 
continues to be a major killer disease in TB-endemic regions. Recently, many emerging evidences from 
the published literature indicate the role of environmental mycobacteria in blocking the processing and 
presentation of BCG antigens and thereby impairing with suboptimal generation of protective T cells. To 
surmount this problem associated with BCG, we constructed a novel lipopeptide (L91) by conjugating 
a promiscuous peptide consisting of CD4+ T-helper epitope of sequence of 91-110 of 16 kDa antigen of 
Mycobacterium tuberculosis to Pam2Cys, an agonist of Toll-like receptor-2. 
Methods: Mice were immunized subcutaneously with 20 nmol of L91, followed by a booster with 10 
nmol, after an interval of 21 days of primary immunization. Animals were sacrificed after seven days of 
post-booster immunization. L91 induced immune response was characterized by the expression of MHC-
II and CD74 on the surface of dendritic cells (DCs) by flowcytometry. Cytokines (IL-4, IL-10, IFN-γ) 
secretion and anti-peptide antibodies were measured by ELISA. 
Results: Self-adjuvanting lipopeptide vaccine (L91) was directly bound to MHC-II molecules and without 
requiring extensive processing for its presentation to T cells. It stimulated and activated dendritic cells and 
augmented the expression of MHC-II molecules. Further, it activated effector CD4 T cells to mainly secrete 
interferon (IFN)-γ but not interleukin (IL)-4 and IL-10. L91 did not elicit anti-peptide antibodies. 
Interpretation & conclusions: The findings suggest that L91 evokes maturation and upregulation of MHC 
class II molecules and promotes better antigen presentation and, therefore, optimum activation of T cells. 
L91 mainly induces effector Th1 cells, as evidenced by predominant release of IFN-γ, consequently can 
mount favourable immune response against M. tuberculosis. As L91 does not provoke the generation of 
anti-peptide antibodies, there is no fear of the efficacy of the vaccine being neutralized by pre-existing 
anti-mycobacterial antibodies in TB-endemic population. In conclusion, L91 may be considered as a 
future potential candidate vaccine against TB.
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 Tuberculosis (TB) is a leading major global threat 
that causes around 2 million deaths annually1. BCG is 
the only available vaccine against TB, which is widely 
administered to control the disease2. BCG engenders 
protection in childhood but fails to do so in adults3. 
There are considerable hurdles associated with BCG 
performance viz. interference in antigen processing, 
masking and blocking due to exposure to environmental 
bacteria, and pre-existence of cross-reactive antibodies4. 
Considerable efforts are being made world-wide to 
develop a better vaccine than BCG and the rewards of 
an ideal global vaccine against TB are being vigorously 
pursued. Recently, several promising TB candidate 
vaccines have shown substantial improvement over 
BCG. These include recombinant BCG (rBCG), 
viral vectors, whole proteins and epitope-based 
vaccines4,5. In our contribution to this effort, we have 
developed a novel vaccination strategy that employs 
a promiscuous peptide epitope that is conjugated to 
the Toll-like receptor-2 (TLR-2) agonist, Pam2Cys4,5. 
Some of the advantages of this lipidated vaccine are 
that (i) it is totally synthetic; (ii) it has self-adjuvanting 
properties; (iii) it targets dendritic cells (DCs); (iv) it 
elicits robust long-lasting memory T cells; and (v) it 
provides enduring protection against Mycobacterium 
tuberculosis4,5. 
 One of the fundamental reasons considered 
for BCG failure in TB-endemic population is the 
interference of non-tuberculous mycobacteria in the 
processing and presentation machinery of antigen 
presenting cells (APCs), especially DCs, and the 
generation of a Th2-like response6. This is also true 
for BCG, which inhibits its own processing and 
presentation7. Further, antibodies generated upon 
exposure to environmental mycobacteria cause the 
clearance of vaccine antigens during immunization8. 
To address these problems, the current study was done 
to demonstrate that the novel vaccine construct L91 
augments the surface expression of mature MHC-
II molecules and inhibits the manifestation of CD74 
(immature MHC molecules) events which contribute 
to enhanced antigen presentation to CD4 T cells. 
Material & Methods
Reagents and antibodies: All standard reagents were 
purchased from Sigma (St. Louis, MO, USA), unless 
otherwise stated. All tissue culture plasticware was 
purchased from BD Falcon (Bedford, MA, USA). 
Fluorochrome conjugated anti-mouse antibodies to 
CD11c (HL-3), CD74 (ln-1), IAd (AMS 32.1), isotype 
controls Hamster IgG1 (G235-2356), IgG2b (A95-1); 
capture and detection antibodies for ELISA for 
interferon (IFN)-γ, interleukin (IL)-4, IL-10 were from 
BD Biosciences (San Diego, CA, USA). Commercial 
Pam2Cys (used as control) was purchased from 
Invivogen (San Diego, CA, USA).
Mice: Female BALB/c mice (6-8 wk, 20±2 g) were 
procured from the Institute of Microbial Technology, 
Chandigarh, India, National Institute of Pharmaceutical 
Education and Research, Mohali, India. The study 
protocol was approved by Institutional Animal Ethics 
Committee. 
Peptides: The promiscuous CD4 T cell peptide epitope 
SEFAYGSFVRTVSLPVGADE (91-110) from the 
16kDa antigen was synthesized and conjugated to 
TLR2-ligand Pam2Cys, as described elsewhere9. This 
lipidated peptide is designated as L91 and free peptide 
as F91.
Immunization: Mice (3-4/group) were immunized 
with L91 (20 nmol) subcutaneously at the base of tail. 
Twenty one days later, a booster dose (10 nmol) was 
administered. Animals were sacrificed seven days 
after receiving the post booster immunization for 
immunological studies.
Expression of MHC-II and CD74 on the surface of 
DCs: The immunophenotyping for the display of 
surface markers was done as described elsewhere5. 
Briefly, bone marrow derived cells (BMDC) (2×106) 
were incubated in Petri plates (60 mm) in the presence 
of granulocyte macrophage colony-stimulating factor 
(GM-CSF) (10 ng/ml) and IL-4 (5 ng/ml) in RPMI-
1640 containing 10 per cent fetal bovine serum (FBS) 
for six days. After three days, the cultures were 
replenished with new medium supplemented with 
growth factors. The cells were harvested on day 7 and 
transferred into 24 well plates (2×105 cells/well). The 
cells were incubated with L91 (3 nmol), F91 (3 nmol) 
and lipopolysaccharide (LPS) (5 µg/ml). After 12 h, 
cells were harvested, washed and examined for surface 
expression of MHC-II and CD74 molecules.
Estimation of IFN-γ, IL-4 and IL-10: Lymphocytes 
(1.5x105/well) isolated from the lymph nodes of mice 
immunized with L91 and F91 were cultured in vitro 
with equimolar (3 nmol) concentrations of either 
L91 or F91 or Pam2Cys in triplicate in ‘U’ bottomed 
96 well microtitre plates for 48 h at 37oC. Later, the 
supernatants were collected from in vitro stimulated 
culture and used for the estimation of IFN-γ, IL-4 
and IL-10 by sandwich ELISA (BD Biosciences, San 
Diego, USA), as per manufacturer’s instructions. 
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Briefly, anti-cytokine (IFN-γ, IL-4, IL-10) (50 µl/well) 
antibodies (Abs) were coated in triplicate in Na2HPO4 
(0.1M, pH 9.0) buffer in flat bottomed 96 well ELISA 
plates overnight at 4oC. Later, the wells were blocked 
with bovine serum albumin (BSA, 1%) and culture 
supernatants (50 µl/well) were added and incubated 
overnight at 4oC. Further, biotinylated secondary Abs 
to the respective cytokine were added and incubated 
at 37oC for 2 h. Avidin-horse radish peroxidase (HRP) 
(50µl/well) was added in each well and plates were 
kept at 37oC for 1 h. Finally, o-phenylenediamine 
(OPD)/H2O2 was added and the optical density was 
determined at 492 nm. Regular procedures of washings 
were followed at each step.
Detection of anti-peptide Abs: Microtitre plates (96 
well) were coated with 50 µl/well of F91 (10 µg/ml) 
in Na2CO3/NaHCO3 (pH, 9.4) buffer for 16 h at room 
temperature. The blocking was performed with BSA 
(1%) for 2 h at 370C. Serum samples (dilution, 1:100) 
obtained from L91 and placebo immunized mice were 
added and plates incubated overnight at 40C. Later, 
HRP-conjugated anti-mouse IgG+IgM+IgA Abs were 
added, followed by incubation at 370C for 1 h. The 
colour was developed using OPD/H2O2 for 20 min at 
370C. Regular procedures for washings were followed 
at each step.
Results & Discussion
L91 promotes the maturation of MHC class II 
molecules: Recently, many studies have attributed the 
decreased processing and presentation that is observed 
with BCG antigens to environmental mycobacteria7 
and downregulation in expression of MHC class II 
molecules on the surface of APCs, which also impairs 
the immune response10. 
Fig. 1. L91 induces MHC-II but downregulates CD74 expression. Bone marrow derived cells (BMDCs) were cultured in medium containing 
L91, F91 or lipopolysaccharides (LPS). The CD11c+ cells were analyzed by flowcytometry for the expression of (a) MHC-II; (b) CD74 
(immature MHC-II). Numbers in the flow cytometry histograms indicate mean fluorescence intensity (MFI) and are representative of 3 
independent experiments; (c) bar graphs depict the change in the ratio of MHC-II to CD74. The cells cultured with medium alone and 
with LPS were used as negative and positive controls, respectively. Data are shown as the mean+SD are from 3 independent experiments. 
***P<0.001.
population should evoke chiefly Th1 responses. Our 
data showed that immunization with L91 provoked 
robust IFN-γ immunity, which is considered to 
play a fundamental role in protection against 
M. tuberculosis.
L91 vaccination fails to provoke Abs: Another important 
reason suggested for BCG failure in TB population is the 
masking and blocking of BCG antigens by antibodies 
elicited by environmental mycobacteria4. Hence in 
these regions, the efficiency of BCG is impaired by the 
pre-existing cross-reactive antibodies produced due 
to exposure to environmental mycobacteria4,16. Even 
though L91 is comprised of CD4 T-helper epitope and 
not a known B cell epitopes, we determined whether 
L91 evokes an Ab response. No anti-peptide Abs were 
detected in the serum of animals immunized with L91 
based on the very low levels of OD (Fig. 3). Recently, 
we have also demonstrated the absence of Abs against 
L91 in the serum of TB patients and PPD+ healthy 
individuals5. These results taken together suggest that 
L91 could be usefully employed as a vaccine for the 
inhabitants of TB-endemic sectors without a fear of its 
activity being neutralized by anti-peptide Abs.
 Our results demonstrate that L91 elicits an immune 
response, the characteristics of which could be very 
useful in imparting protective immunity against M. 
Fig. 2. L91 elicits Th1 but not Th2 response. The cells obtained 
from immunized mice were cultured with L91, F91, Pam2Cys 
or medium alone for 48 h. Secretion of cytokines in the culture 
supernatants was measured by ELISA. The results depicted as bar 
diagrams show the change in ratio of (a) IFN-γ and IL-4; (b) IFN-γ 
and IL-10. Data are expressed as the mean ± SD and are pooled 
data from 3 independent experiments with 3-4 mice per group. 
**P<0.003.
 Pam2Cys is known to upregulate the expression of 
MHC molecules5. Hence it became necessary to check 
the influence of L91 in affecting the expression of 
MHC molecules on the surface of APCs. In particular, 
the display of MHC-II molecules on the surface of 
DCs was monitored, since they play a cardinal role in 
activating naïve T cells. It was interesting to observe 
that L91 significantly enhanced the display of MHC-
II molecules on the surface of DCs (Fig. 1a). This 
increase was comparable to that observed with DCs, 
which were incubated with LPS (positive control). 
In contrast, F91 failed to induce any enhancement 
in MHC-II expression. It was also noticed that L91 
downregulated the expression of immature MHC-II 
molecules (CD74) (Fig. 1b). A similar trend was also 
observed in the case of LPS and F91. The experiments 
depicting enhancement in the exposition of MHC-II and 
decrease in CD74 signify that L91 can activate DCs and 
therefore, may be successful in TB-endemic regions; 
where exposure to environmental mycobacteria and 
BCG immunization is known to downregulate MHC 
molecules. Further, it has also been reported that BCG 
infected THP1 cells show reduced expression of MHC 
class II and upregulation of CD74 (immature MHC)11. 
Furthermore, decreased expression of MHC-II has 
been reported at the surface of RAW (mouse leukaemic 
monocyte macrophage cell line) cells infected with 
M. avium12. A significant difference in the ratio of 
MHC-II/CD74 molecules on the surface of DCs was 
observed (Fig. 1c). We have shown earlier that L91 can 
also induce the expression of CD80, CD86 and CD40 
co-stimulatory molecules and activate DCs to produce 
IL-6 and IL-125.
L91 immunization elicits secretion of IFN-γ: The role 
of Th1 cells and the cytokine IFN-γ has been very well 
established in protection against TB13. In contrast, Th2 
cells and their associated cytokines (IL-4, IL-10) are 
correlated with the progression of disease13. Therefore, 
the production of Th1 and Th2-like cytokines was 
monitored in the mice immunized with L91 or F91. It 
was of interest to note that L91 significantly (P<0.003) 
augmented release of IFN-γ by effector T cells when 
compared to IL-4 and IL-10 (Fig. 2a, b). We did not 
observe much secretion of cytokines in the cells pulsed 
with F91 or Pam2Cys.
 In TB endemic population, individuals have 
compromised Th1 and Th2 biased immunity due to 
helminth and non-tuberculous bacterial infection4. 
Further, BCG fails to mount Th1 immunity14,15. Hence 
it is crucial that the vaccine developed against this 
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Fig. 3. L91 fails to evoke antibody response upon immunization. 
The presence or absence of anti-peptide Abs was examined in 
the serum of mice immunized with L91 or placebo. M1, M2, M3 
represent the data from individual mice. The level of OD indicates 
that the Ab is negative in serum of L91 vaccinated mice. The data 
(OD) of the bar diagram are represented as the mean ± SD (three 
independent experiments, **P<0.003). 
tuberculosis. It is important to note here that L91 has 
self-adjuvanting properties and it works in genetically 
distinct populations5. L91 has been designed to 
overcome the shortcomings that are associated with 
BCG during vaccination in TB-endemic population. 
Based on our current results and published work4,5, it 
can be speculated that L91 has significant potential 
to be considered as a future vaccine candidate against 
M. tuberculosis.
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